Telesis Bio Q3 2023 EPS $(0.37) Misses $(0.30) Estimate, Sales $5.56M Miss $7.40M Estimate
Portfolio Pulse from vinayak@benzinga.com
Telesis Bio (NASDAQ:TBIO) reported Q3 2023 earnings with an EPS of $(0.37), missing the $(0.30) estimate by 23.33%, and sales of $5.56M, missing the $7.40M estimate by 24.81%. Compared to last year, EPS improved by 11.9% while sales decreased by 16.64%.
November 13, 2023 | 9:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Telesis Bio's Q3 EPS of $(0.37) missed estimates by 23.33% and sales of $5.56M missed by 24.81%, indicating a potential negative short-term impact on TBIO's stock price.
Missing both EPS and sales estimates significantly, especially by over 20%, is typically seen as a negative indicator for a company's financial performance and can lead to a decrease in investor confidence. This often results in a negative short-term reaction in the stock market. Although the EPS shows an improvement from the previous year, the decline in sales and the miss on both fronts overshadow this positive aspect.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100